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Acute treatment with the chloroform fraction of Dioclea virgata (Rich.) Amshoﬀ (CFDv) in mice produced decreased ambulation
and sedation in the behavioral pharmacological screening. Doses of 125 and 250mg/kg CFDv decreased latency of sleep onset in
the test of sleeping time potentiation. In the open ﬁeld, animals treated with CFDv reduced ambulation and rearing (250mg/kg),
as well as defecation (125; 250mg/kg). Regarding the antinociceptive activity, CFDv (125, 250, 500mg/kg) increased latency to
ﬁrst writhing and decreased the number of writhings induced by acetic acid. In the formalin test, CFDv (250mg/kg) decreased
paw licking time in the ﬁrst and second phases indicating antinociceptive activity that can be mediated both peripherally and at
the central level. CFDv did not aﬀect motor coordination until 120 minutes after treatment. CFDv shows psychopharmacological
eﬀects suggestive of CNS-depressant drugs with promising antinociceptive activity.
1.Introduction
Natural products, including medicinal plants, have been the
primary source for obtaining new drugs with therapeutic
potential throughout history. It is estimated that approxi-
mately half of the drugs in use are derived from natural
products. According to the World Health Organization,
poverty and lack of access to modern medicine leads from
65% to 80% of the world population in developing countries
to critically depend on plants for primary health care [1].
Dioclea virgata (Rich.) Amshoﬀ, commonly known as
“cip´ o-pixuma” or “feij˜ ao-de-boi,” is an extremely hairy
woody vine and member of the family Fabaceae (Legumi-
nosae) [2]. Its leaves are popularly used in decoction to treat
fever and malaria [3].
Although the popular uses are reported, the species
is poorly scientiﬁcally investigated, being found only in
one immunological study [4] with seeds of Dioclea virgata
(Rich) Amshoﬀ. Furthermore, Almeida et al. (1999) [5]
performedapreliminarybehaviorassessmentinmicetreated
intraperitoneally with ethanolic crude extract of Dioclea
virgata suggesting a possible depressant action of this plant.
Other members of the family Fabaceae have already
demonstrated activity on the central nervous system (CNS),
such as Clitoria ternatea, which showed nootropic, anxi-
olytic, antidepressant, and anticonvulsant activities in mice
and rats [6]; Desmodium gangeticum showed promising
activity to improve memory and potential for treatment
of dementia and Alzheimer’s [7]; Erythrina velutina and
Erythrina mulungu, popularly used in Brazil, showed CNS-
depressantproﬁleandanticonvulsantactivity,possiblyacting
on the glycinergic system [8]; Dioclea grandiﬂora Mart ex
Benth demonstrated CNS-depressant eﬀects such as: anti-
Parkinsonian [9] and antinociceptive activity in mice [10,
11].
The aim of this study was to investigate the possible
psychopharmacological eﬀects of the chloroform fraction of
DiocleavirgatausinginvestigativemethodologiesontheCNS
activity in mice, in order to expand scientiﬁc knowledge
about the species.2 Journal of Biomedicine and Biotechnology
2.MaterialandMethods
2.1. Animals. Male and female (nulliparous and nonpreg-
nant)3-month-oldSwiss mice(Mus musculus)(30–40gbody
weight) were obtained from the vivarium of the Laboratory
of Pharmaceutical Technology of UFPB, where they were
born and bred. The animals were housed under standard
laboratory conditions, with a 12-hour light/12-hour dark
photoperiod, with the light period beginning at 06:00 hour.
They were fed on rat chow pellets and received water ad
libitum. The room temperature was kept at 21 ± 1◦Ca n d
all experiments were conducted between 12:00 and 17:00
hour.
All experiments were approved by the Ethics Committee
on Animal Research of LTF/UFPB, under the opinion no.
0503/07.
Foreachtest,animalswererandomlyselectedandequally
divided into groups of 10 animals (ﬁve males and ﬁve
females). All animals were taken to the testing environment
at least one hour before the experiments and not tested more
than once. The behavioral testing protocols were conducted
under blind conditions.
2.2. Botanical Material. Leaves and branches of Dioclea
virgata (Rich.) Amshoﬀ were collected on 04/26/2006 in
Santa Rita, Para´ ıba, Brazil, being the botanical identiﬁcation
andmorphologicaldescriptionperformedbyProf.Dr.Maria
de F´ atima Agra from the botany sector, Federal University
of Para´ ıba (UFPB), and authenticated in the Herbarium
Lauro Pires Xavier (JPB) UFPB, where a voucher specimen
is deposited under the code AGRA 5993 JPB.
2.3. Preparation of the Chloroform Fraction of Dioclea Virgata.
Preparation of the chloroform fraction of Dioclea virgata was
performed by Prof. Dr. Bhattacharyya’s team—LTF/UFPB.
LeavesandbranchesofDiocleavirgataweredried,powdered,
and extracted with methanol. The extract was concentrated
in a Rotavapor apparatus, obtaining the crude methanol
extract. Subsequently, it was partitioned with CHCl3/H2O
(1:1),obtainingthewaterandchloroformphases.Avacuum
ﬁltration of the latter was performed to obtain the chloro-
form extract free of inorganic particles. It was placed on a
silica gel column and eluted with diﬀerent solvents following
an increasing polarity order: hexane, chloroform, ethyl
acetate, and methanol. The chloroform fraction obtained by
this column was used in the experiments.
2.4. Substances. Glacial acetic acid (Synth-USA), distilled
water (LTF/UFPB-Brazil), sodium chloride (Merck-USA),
morphine chloride (Merck-USA), ethanol (LTF/UFPB-
Brazil), 37% formaldehyde (Vetec-Brazil), 2.5% formalin
(LTF/UFPB-Brazil), sodium pentobarbital (Sigma-Aldrich-
USA), Tween 80 (Merck-USA), and Salicylic acid (Sigma-
Aldrich, USA).
Drugs were administered intraperitoneally (i.p.) at
0.1mL/10g of mice. Doses were prepared minutes before
use,dissolvedindistilledwateror0.9%salinesolution.CDFv
was dissolved with 5% Tween 80.
2.5. Pharmacological Evaluation
2.5.1. Behavioral Pharmacological Screening and LD50 Cal-
culation. Animals were divided into groups of 10 mice
and treated with diﬀerent CFDv doses (between 125
and 1000mg/kg) or vehicle intraperitoneally. Groups were
observed at 30, 60, 120, 180, and 240 minutes after the
respective treatments; behaviors or changes indicating phar-
macological activity on the central nervous system were
recordedaccordingtothemethoddescribedbyAlmeidaetal.
(1999) [5].
Assessment of possible toxic eﬀects was carried out with
the same animals used in the behavioral screening under
72h observation to record the deaths occurrence and LD50
determination.
2.5.2. Pentobarbital-Induced Sleeping Time. This test eval-
uates the substance-induced depressive activity, since the
latency reduction to sleep onset and/or additional increase in
sleep time induced by pentobarbital from treatment with the
test substance is indicative of CNS-depressant activity [12].
Thirty minutes after the respective treatments, animals
received 40mg/kg pentobarbital sodium (intraperitoneally)
and were placed in individual boxes to record the hypnotic
eﬀect of latency and sleep time [13, 14].
2.5.3. Rota Rod Test. The method proposed by Dunham
and Miya (1957) [15] involves placing mice on a rotating
bar and measuring the eﬀect of muscle relaxation or motor
incoordination produced by the drug under study [16].
Animals were preselected without substance administra-
tion through a criterion of permanence in the Rota Rod
machine’s rotary bar (Rota-Rod Ugo Basile mod. 7750) at
a constant speed of 7 revolutions per minute (7rpm) for at
least three minutes [17].
Twenty-four hours after preselection, mice deemed suit-
able were divided into four groups of 10 animals. Motor
performance was measured as time spent walking on a
rotating rod (7rpm) during three minute trials evaluated at
30,60,and120minutesafteri.p.injectionofCFDv(125,250,
and 500mg/kg) or vehicle [11, 18].
2.5.4. Open-Field Test. This test evaluates the exploratory
activity of animals, since their natural tendency is exploring
the new environment, despite the stress and conﬂict that is
caused [19].
The animals were submitted individually for a period
of 5 minutes to an open-ﬁeld test (Insight mod. EP 154C),
30 minutes after pretreatments. The parameters observed
included: ambulation (recorded by the number of segments
crossed by the animal with four legs), grooming, number of
rearing occurrences and number of fecal masses [20]. The
parameters observed were performed live.
2.5.5.AceticAcid-InducedAbdominalWrithing. Asol utionof
0.8% acetic acid intraperitoneal injection in mice causes a
local irritation, characterized by writhing followed by hind
limbs extensions due to the nociceptor stimulation [21].Journal of Biomedicine and Biotechnology 3
Table 1: Summary of multiple tests conducted with CFDv and their results.
Methods Results
General tests
Behavioral pharmacological screening CNS-depressant activity
Pentobarbital-induced sleeping time There was no eﬀect on total sleeping time
Rota Rod test Absence motor abnormality or neurotoxicity
Open-ﬁeld test Sedative action
Speciﬁc tests (antinociceptive activity) Acetic acid-induced abdominal writhing Antinociceptive activity
Formalin test Activity may probably be mediated in the CNS level
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Figure 1: Eﬀect of CFDv on the latency to pentobarbital-induced
sleep onset in mice. Values are expressed as mean ± S.E.M. (n =
10), ∗P<0.05 versus control group. ANOVA followed by Dunnett’s
Multiple Comparison Test.
Usually,drugswithanalgesicpropertiesreduceorinhibitthis
behavior [22].
Five groups of 10 mice received the following pretreat-
ments by i.p. route: vehicle, 6mg/kg morphine or CFDv
(125, 250, and 500mg/kg). Thirty minutes after initial
pretreatment, animals received a solution of 0.8% acetic acid
in distilled water (0.1mL/10g) injected i.p. and were placed
in individual boxes for 20 minutes to record the latency to
the ﬁrst writhing and number of writhings [23].
2.5.6.FormalinTest. Inthis test,formalinsolutionisinjected
intothemouse’ssubplantarregionleadingtothestimulation
of nociceptors [24]. The response produced by formalin is
biphasic: the ﬁrst phase, usually within the ﬁrst 5 minutes
after formalin injection, the response is neurally mediated;
then there is an interphase of about 10 minutes characterized
by inhibitory pain mechanisms and the second phase
(15–30 minutes), and the response follows the release of
inﬂammatory mediators [25].
Four groups of 10 mice received the following pretreat-
ments by i.p. injection: vehicle, 250mg/kg of CFDv, 6mg/kg
morphine, or 100mg/kg acetylsalicylic acid (ASA). After
30 minutes, 20μL of 2.5% formalin solution was injected
into the subplantar region of the mice’s right hind paw.
The parameter recorded was total time spent paw licking
after formalin injection during both pain phases: ﬁrst 5
minutes (neurogenic pain) and between 15 to 30 minutes
(inﬂammatory pain) [25].
2.6. Statistical Analysis. Data were expressed by mean ±
standard error (S.E.M.) or percentage and analyzed for
statistical signiﬁcance using one-way analysis of variance
(ANOVA) followed by Dunnett’s multiple comparison test
for parametric measures or Kruskal-Wallis test followed
by Dunn’s multiple comparison test for nonparametric
measures. Tests were performed using the GraphPad Prism,
version 4.0 (GraphPad Software Incorporated, San Diego,
Calif, USA). The diﬀerence between groups was considered
signiﬁcant at P<0.05.
3. Results
Table 1 shows a summary of multiple tests conducted with
CFDv and their results.
3.1. Behavioral Pharmacological Screening and LD50. At the
dose of 125mg/kg behavioral eﬀects resulting from the
treatment with chloroform fraction were not veriﬁed.
Animals treated with 250 and 500mg/kg CFDv showed
decreased ambulation at 30 and 60 minutes, and those
receiving 500mg/kg also showed diminished touch response.
After treatment with 1000mg/kg mice showed decreased
ambulation and reduced touch response, sedation, presence
of writhing, and increased defecation up to 30 minutes. At
60 minutes of observation, animals showed reduced touch
response, sedation, and diminished ambulation. Doses of
125, 250, and 500mg/kg CFDv did not cause death of any
mice. There were 10% deaths in the group of animals treated
with 1000mg/kg. From 1000mg/kg, it was not possible to
solubilize the fraction under study and the LD50 could not be
calculated.
3.2. Pentobarbital-Induced Sleeping Time. As illustrated in
Figure 1,sleeplatencydecreasedsigniﬁcantly(P<0.05)after
CFDv administration at 125 (193.2 ± 8.2s) and 250mg/kg
(190.1 ± 7.1s) compared to the control group (236.6 ±
8.5s). The dose 500mg/kg (206.5 ± 19.7s) did not aﬀect
signiﬁcantly this parameter.4 Journal of Biomedicine and Biotechnology
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Figure 2: Eﬀect of CFDv on the pentobarbital-induced sleeping
time in mice. Values are expressed as mean ± S.E.M. (n = 10).
ANOVA followed by Dunnett’s Multiple Comparison Test.
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Figure 3: Eﬀect of CFDv on the mice’s motor coordination on
the Rota Rod test after 30 minutes of doses administration. Values
express the total permanence time of animals in the revolving bar.
Values are expressed as mean ± S.E.M. (n = 10). Kruskal-Wallis test
followed by Dunn’s Multiple Comparison Test.
None of the CFDv doses (125, 250, and 500mg/kg) was
able to modify signiﬁcantly the sleeping time of animals
compared with the control group (Figure 2).
3.3. Rota Rod Test. None of the CFDv doses was able
to reduce the animals’ permanence time on the revolving
bar at 30 minutes after treatment (125mg/kg: 175.2 ±
3.6s; 250mg/kg: 179.9 ± 0.1s; 500mg/kg: 163.8 ± 13.2s)
compared with the control group (179.8 ± 0.2s). No
signiﬁcant impairment in motor activity was detected at 60
minutes (Control: 177.4 ± 1.7s; 125, 250, and 500mg/kg
CFDv, 175.3 ± 3.4s; 178.9 ± 1.1s; 176.0 ± 3.7s resp.) and at
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Figure 4: Eﬀect of CFDv on the mice’s motor coordination on
the Rota Rod test after 60 minutes of doses administration. Values
express the total permanence time of animals in the revolving bar.
Values are expressed as mean ± S.E.M. (n = 10). Kruskal-Wallis test
followed by Dunn’s Multiple Comparison Test.
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Figure 5: Eﬀect of CFDv on the mice’s motor coordination on the
Rota Rod test after 120 minutes of doses administration. Values
express the total permanence time of animals in the revolving bar.
Values are expressed as mean ± S.E.M. (n = 10). Kruskal-Wallis test
followed by Dunn’s Multiple Comparison Test.
120 minutes (125mg/kg: 177.5 ± 1.9s; 250mg/kg: 171.8 ±
7.3; 500mg/kg: 162.3 ± 14.7s; Control: 178.5 ± 1.0s) after
treatment with CFDv (Figures 3, 4,a n d5).
3.4. Open-Field Test. Animals receiving 250mg/kg CFDv
showed reduction in ambulation (94.6 ± 9.1) compared to
the control group (140.8 ± 14.0) (Figure 6).
Grooming behavior in the groups treated with CFDv
(125, 250 and 500mg/kg) was not changed (15.3 ± 5.8, 7.8 ±
2.4 and 15.1 ± 5.6 seconds, resp.) compared to the control
group (3.1 ± 1.4 seconds).Journal of Biomedicine and Biotechnology 5
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Figure 6:EﬀectofCFDvontheambulationinmicesubjectedtothe
open ﬁeld apparatus for 5 minutes. Values are expressed as mean ±
S.E.M. (n = 10), ∗P<0.05 versus control group. ANOVA followed
by Dunnett’s Multiple Comparison Test.
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Figure 7: Eﬀect of CFDv on the rearing in mice subjected to the
open ﬁeld apparatus for 5 minutes. Values are expressed as mean ±
S.E.M. (n = 10), ∗P<0.05 versus control group. ANOVA followed
by Dunnett’s Multiple Comparison Test.
Only animals treated with 250mg/kg CFDv (25.8 ± 4.2)
decreased signiﬁcantly the number of rearing occurrences
compared to the control (43.4 ± 4.7) (Figure 7).
Furthermore, the doses of 125mg/kg (0.3 ± 0.1) or
250mg/kg (0.2 ± 0.1) signiﬁcantly reduced the number of
fecal masses compared to the control (1.4 ± 0.2) whilst the
one of 500mg/kg (0.8 ± 0.3) did not (Figure 8).
3.5. Acetic Acid-Induced Abdominal Writhing. In all groups
treated with CFDv (125mg/kg: 722.5 ± 131.0s; 250mg/kg:
999.6 ± 106.1s; 500mg/kg: 890.3 ± 79.47s), there was an
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Figure 8: Eﬀe c to fC F D vo nt h ed e f e c a t i o n( n u m b e ro ff e c a l
masses) in mice subjected to the open ﬁeld apparatus for 5 minutes.
Values are expressed as mean ± S.E.M. (n = 10), ∗P<0.05,
∗∗P<0.01 versus control group. Kruskal-Wallis test followed by
Dunn’s Multiple Comparison Test.
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Figure 9: Eﬀect of CFDv on the latency on acetic acid-induced
abdominal writhings in mice. Values are expressed as mean ±
S.E.M. (n = 10), ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001 versus
control group. Kruskal-Wallis test followed by Dunn’s Multiple
Comparison Test.
increased latency to the ﬁrst writhing appearance compared
to the control group (278.2 ± 25.4s), similar to morphine
(1127.0 ± 73.5s) (Figure 9).
As shown in Figure 10, there was a decrease in the
number of writhings in all groups for which the CFDv was
administered (125mg/kg: 8.7 ± 2.7; 250mg/kg: 3.6 ± 1.8;
500mg/kg: 5.3 ± 1.7) compared to control (24.3 ± 2.8).6 Journal of Biomedicine and Biotechnology
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Figure 10: Eﬀect of CFDv on the number of writhings on acetic
acid-induced abdominal writhings in mice. Values are expressed
as mean ± S.E.M. (n = 10), ∗P<0.05, ∗∗∗P<0.001 versus
control group. Kruskal-Wallis test followed by Dunn’s Multiple
Comparison Test.
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Figure 11:EﬀectofCFDvon1stphaseonformalin-inducedlicking
in mice. Values are expressed as mean ± S.E.M. (n = 10), ∗∗P<
0.01 versus control group. ANOVA followed by Dunnett’s Multiple
Comparison Test.
3.6. Formalin Test. Mice treated with 250mg/kg CFDv
showed signiﬁcant reduction of paw licking time in the ﬁrst
phase, with 60.9 ± 9.8 seconds compared to control 91.1 ±
6.8 (Figure 11). Thus, we obtained a result similar to that
of the standard group treated with morphine (37.5 ± 4.8).
In the group treated with 100mg/kg ASA, there was no
signiﬁcantreductionintheparameterevaluated(81.7 ±1.5).
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Figure 12: Eﬀect of CFDv on 2nd phase on formalin-induced
licking in mice. Values are expressed as mean ± S.E.M. (n = 10),
∗∗P<0.01 versus control group. ANOVA followed by Dunnett’s
Multiple Comparison Test.
As the result shown in Figure 12, CFDv at 250mg/kg
(12.3 ± 10.4s) reduced the paw licking time during the sec-
ond phase of the formalin test when compared with the
control group (213, 3 ± 51.6s), morphine (33.7 ± 8.1s) and
ASA (89.7 ± 11.5s).
4. Discussion
This work consisted of investigating the CFDv antinocicep-
tive activity. To observe the suggestive eﬀect on the central
nervous system (CNS) and/or autonomic nervous system
(ANS) and possible toxic eﬀects, we performed a behavioral
pharmacological screening with CFDv at the doses of 125,
250, 500 and 1000mg/kg, administered intraperitoneally in
mice [26].
Eﬀectsobservedonthedosesof250,500,and1000mg/kg
suggested a possible CNS-depressant activity, for example,
reduced ambulation, impaired touch response and sedation
[5, 27, 28].
These results are similar to the ones reported by Almeida
et al. [5] who observed CNS-depressant activity in mice
subjected to behavioral screening treated with crude ethanol
extract of Dioclea virgata (Rich.) Amshoﬀ.
Pentobarbital-induced sleeping time, Rota Rod, and
open-ﬁeld tests were chosen as general tests to investigate the
possible CFDv’s psychodepressant activity observed in the
screening.
Through the test for sleeping time, potentiation induced
by sodium pentobarbital is possible to assess whether the
tested substance has neurosedative action or a hypnotic
proﬁle [29].
Pentobarbital, as a barbiturate, acts primarily at the
synapses where the neurotransmission is mediated by GABA
in type-A GABAergic receptors. These receptors are charac-
terizedbybeingionchannelspermeabletochloride,inwhichJournal of Biomedicine and Biotechnology 7
barbiturates act by increasing conductance to this ion and
thus enhancing the inhibitory GABA eﬀect that is the main
central inhibitory neurotransmitter [30].
It is worth mentioning that the test for pentobarbital-
induced sleeping potentiation is not a speciﬁc test, since
drugs devoid of central action, such as those that decrease
oxygen uptake by tissues or even those that cause vasodi-
lation or vasoconstriction, potentiate the sleeping time by
interfering with the pentobarbital biotransformation in the
cytochrome P450 complex, and thus may produce the same
actions of CNS-depressant drugs [31, 32].
Latency decrease was observed in this test period con-
sidered between the pentobarbital administration and the
hypnotic eﬀect onset [33], being characterized by loss of
righting reﬂex in animals treated with 125 and 250mg/kg
CFDv. However, the fraction studied did not aﬀect the
sleeping time when compared to the control group.
A possible myorelaxing activity as well as the animal’s
motor coordination was evaluated in the test using the Rota
Rodthroughthetotaltimeofpermanenceintherotating bar
[34]. The lack of motor coordination in the Rota Rod test is
a characteristic of pharmacological agents, such as skeletal
muscle relaxants or drugs that reduce the CNS activity,
such as neuroleptics, anxiolytics, sedatives, and hypnotics
[35, 36].
It is noteworthy, however, that the Rota Rod test is a
nonspeciﬁc method, since it measures neurological eﬀects,
stimulants, and depressants on motor coordination indis-
criminately to which is also assigned the term neurotoxicity
[37]. As no signiﬁcant reduction in animals’ permanence
time in the revolving bar at 30, 60, and 120 minutes after
the three doses studied (125, 250, and 500mg/kg CFDv) has
occurred, it may indicate that the CFDv treatment does not
interfere with motor coordination, thus ruling out a muscle
relaxant eﬀect or even a neurotoxicity that is common to
some drugs with CNS-depressant proﬁle.
The open-ﬁeld test, originally described by Hall in 1934
for studying emotionality in rats, is a method used to
assess exploratory behavior, reaction to the new, anxiety,
memory,andstimulatingactivity,inadditiontosedationand
locomotor activity [20, 38]. Animals subjected to open-ﬁeld
test showed decrease in ambulation as well as in the number
of rearing times when receiving 250mg/kg CFDv. There was
also defecation reduction for animals treated with 125 and
250mg/kg CFDv, but there was no eﬀect with the 500mg/kg
dose. Grooming was the only parameter that did not change
with the three doses tested.
The inhibition of ambulation and rearing is related to
drugs with sedative action [20, 39]. Research shows that a
highlevelofemotionalityisrelatedtoincreasesindefecation;
anxiolyticdrugsreducedefecation[40,41].However,further
studies to investigate whether CDFv caused changes in
smooth muscle activity of the gastrointestinal system would
be needed. It cannot be concluded that CDFv reduced
defecation by reducing anxiety. According to Shaw et al.
2007 [41], grooming usually increases in situations of fear
or anxiety in rodents being an adaptation index to a stressful
situation. Anxiolytic drugs reduce this behavior in the open
ﬁeld test.
To analyze the possible CFDv antinociceptive activity,
twobehavioralmethodswereusedtoinducenociception:the
acetic acid-induced writhing test, which produces chemical
noxious stimulation in the periphery system with a medullar
component, and the formalin test, animal model with
nociceptors stimulation that results in a pain-indicative
behavior biphasic model.
The acetic acid-induced abdominal writhing test, an
animal model for nociceptor stimulation to screening drugs
with analgesic activity based on irritation caused after
intraperitoneal injection of acetic acid solution. This injec-
tion can produce a peritoneal inﬂammation characterized by
contractions of abdominal muscles followed by hind limbs
extension [21, 23].
Although simple, fast, and reliable to assess the antinoci-
ceptive activity of substances [42], is a low speciﬁc method
since it is sensitive to nonsteroidal anti-inﬂammatory drugs,
narcotics and other centrally acting drugs, anticholinergics,
and antihistamines [43, 44].
TreatmentwithCFDvcausedincreasedlatencytotheﬁrst
writhinginmiceandreductioninthenumberofwrithingsin
the three experimental groups, similar to the standard group
treated with morphine; being observed that changes in these
parameters were not dose-dependent.
Theseresultsaresimilartothose reportedbyBatistaetal.
(1995) [10] with aqueous fraction and ﬂavonoid dioclein
obtained from the ethanol extract of Dioclea grandiﬂora,
as well as those of S´ a et al. [11]c o n d u c t e dw i t hDioclea
grandiﬂora seed pod. Among other plant species of the
family Fabaceae evaluated in the acetic acid methodology,
it may be mentioned that the extract of Erythrina velutina
and Erythrina mulungu, the aqueous extract of Desmodium
gangeticum DC, as well as the extract and some fractions
from Erythrina crista-galli, reduced the number of writhings
in rodent studies [8, 45, 46].
In an attempt to better characterize the CFDv activity
found in the acetic acid-induced writhing test, the formalin
model was employed and CFDv injected at a dose of
250mg/kg. Formalin produced a diﬀerent biphasic response
where analgesics may act diﬀerently in the ﬁrst and second
trial phases [47]. The ﬁrst phase of the formalin model lasts
a few minutes and begins immediately after the injection of
formalin in the plantar surface of the animal and is due to
release of the substance P and direct chemical stimulation
of aﬀerents, especially C ﬁbers [48, 49]. It reﬂects the neu-
rogenic component of nociception being sensitive to drugs
that act primarily on the central system, such as opioids [50].
Between the ﬁrst and second phases of the formalin test,
there is a rest period called the “interface” which occurs
due to an activation of inhibitory processes GABA-mediated
mechanisms, since the type-A GABAergic agonists inhibits
the decrease of pain manifestations during this period [51,
52].
The inﬂammatory component of the nociceptive
response (second phase) starts after 10 to 15 minutes of
“interface” and is the result of inﬂammatory mediator
release such as bradykinin, histamine, sympathomimetic
amines, tumoral-α necrosis factor, and interleukins [50]o ra
facilitation of spinal synaptic transmission [53, 54].8 Journal of Biomedicine and Biotechnology
It is interesting to consider that centrally acting drugs
such as opioids inhibit both formalin test phases. Neverthe-
less,peripheralactingdrugssuchasanti-inﬂammatorydrugs
are eﬀective only in the second phase [49, 55]. According to
HunskaarandHole[25],thesecondphaseissensitivetoboth
NSAIDs and corticosteroids.
Similar to the results of S´ a et al. (2010) [11]w i t hDioclea
grandiﬂora, CFDv produced nociceptive response reduction
inbothformalintestphases,similarlytomorphineandother
centrally acting analgesic drugs, which are widely eﬀective in
preventing the pain formalin-induced pain in both testing
phases [44], thus indicating that the CFDv antinociceptive
eﬀect presents a central component and a possible anti-
inﬂammatory activity. As expected, the analgesic eﬀect
produced by ASA was evident only in the second phase of
this test [56].
5. Conclusions
Data presented in this study showed that CFDv exerts
current antinociceptive activity with little or no eﬀects and
no dose-response relationships in tests for CNS depression
or sedation. The reduction in pain responsiveness seemed
similar to that morphine dose-induced, indicating that this
activity may probably be mediated in the CNS level. In
addition, CFDv did not promote muscle relaxation and
incoordination, or neurotoxicity by any alteration in the per-
manence time in the Rota Rod test’s rotating bar. However,
further studies are necessary to elucidate the mechanism
behind the observed eﬀects.
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